Dopamine Receptor Agonist

MCL-524 is a highly selective full agonist of the dopamine D₂ receptor with a K_d value of 1.34 nM. MCL-524 specifically binds to the high-affinity state of the dopamine D₂ receptor; this binding is abolished by guanylylimidodiphosphate, and it can distinguish between D₂^high and D₂^low sites. MCL-524 is applicable to research related to Parkinson's disease and schizophrenia.

Naxagolide hydrochloride is an agonist of D2. Naxagolide hydrochloride can be used in study Parkinsonism.

CGS 15873A is an orally active benzopyranopyridine derivative. CGS 15873A has selective dopamine receptor activation activity. CGS 15873A can be used for research on schizophrenia or Parkinson's disease.

PD 158771 is an antipsychotic agent that functions as a partial agonist for D₂ /D₃ receptors (K_i = 42.0/13.7 nM) and as an agonist for 5-HT_1A receptors (K_i = 2.6 nM). PD 158771 can be utilized in antipsychotic research.

Pramipexole-d₇ dihydrochloride is the deuterium labeled Pramipexole dihydrochloride. Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with K_is of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS).

SK609 hydrochloride is a dopamine D3 receptor (D3R) selective agonist with an EC₅₀ of 1109 nM. SK609 hydrochloride has the potential for parkinson research.

Nolomirole (CHF 1035) is an orally active and selective DA2 dopaminergic receptor/α2-adrenoceptor agonist. Nolomirole attenuates the heart failure signs in the Monocrotaline (HY-N0750)-induced congestive heart failure model. Nolomirole increases cardiac output.

Proterguride is a potent dopamine receptor agonist. Proterguride also shows antagonistic properties at the histamine H(1) receptor and alpha(1)-adrenoceptor and partially agonize serotonergic 5-HT2A/B receptor. Proterguride can be used for the research of neurological disease, such as Parkinson's disease .

D-520 is a potent and brain-penetrant dopamine D2/D3 agonist (D2 EC₅₀ = 4.73 nM, K_i = 41.8 nM; D3 EC₅₀ = 2.18 nM, K_i = 0.35 nM). D-520 inhibits the formation of Aβ aggregates in vitro and promotes the disaggregation of both alpha-synuclein (α-syn) and Aβ aggregates. D-520 exhibits efficacious activity in animal models of Parkinson’s disease (PD). D-520 can be used for PD and PD with dementia (PDD) research^[1][2].

PF2562 (Example 6), a dopamine D1 ligand, ascts as a dopamine D1 agonist or partial agonist. PF2562 binds to human D1 receptor with a K_i of 113 nM. PF2562 exhibits activity against human D1 cAMP with an EC₅₀ of 568 nM in HTRF assay.

ARN25657 is a dual-acting D3R/GSK-3β modulator. ARN25657 has both partial D3R agonist activity (EC₅₀ = 15.2 nM, K_i =1.5 nM) and potent GSK-3β inhibitor activity (IC₅₀ = 19.3 nM). ARN25657 exhibits excellent GSK-3β selectivity over FYN, PKA, and CDK5/p35. ARN25657 inhibits P-glycoprotein (P-gP)-mediated acetoxymethyl calcein efflux and improves in vitro ADME properties while maintaining a balanced dual-target profile. ARN25657 is useful for studying bipolar disorder and related neuropsychiatric disorders.

Piribedil dihydrochloride is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil dihydrochloride is also a α2-adrenoceptors antagonist. Piribedil dihydrochloride can inhibit MLL1 methyltransferase activity (EC₅₀: 0.18 μM). Piribedil dihydrochloride has the potential for the research of parkinson's disease, circulatory disorders, cancers.

A68930, as a dopamine D1 receptor agonist, can be used for the research of bronchiectasis.

(Rac)-Rotigotine (N-0437) is a racemate of Rotigotine. Rotigotine is a full agonist of dopamine receptor, a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor, with K_is of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor.

BP 897 is a potent and partial dopamine D3 receptor agonist and a weak D2 receptor antagonist. BP 897 displays a high affinity at the dopamine D3 receptor (K_i=0.92 nM) and a 70 times lower affinity at the D2 receptor (K_i=61 nM).

Tau-aggregation-IN-1 (Compound D-519) is a tau441 protein aggregation inhibitor with an IC₅₀ of 21 µM. Tau-aggregation-IN-1 is also a dopamine D₂ and D₃ receptor agonist.

FMJ-01-042 is a blood-brain barrier-permeable, low-efficacy partial agonist with high affinity (Kᵢ = 4.33 nM) and exceptional subtype selectivity for the dopamine D4 receptor. FMJ-01-042 exhibits good metabolic stability and is suitable for research on neurological and psychiatric disorders.

Dopamine D2 receptor agonist-4 is a blood-brain barrier permeable Dopamine D2 receptor agonist with an EC₅₀ value of 0.03 nM. Dopamine D2 receptor agonist-4 reduces intracellular cAMP levels. Dopamine D2 receptor agonist-4 acts as a Ferroptosis inhibitor and iron chelator, selectively chelating iron ions, reducing intracellular ferrous ion levels, and exerting cytoprotective effects against iron-dependent ferroptosis in vitro. Dopamine D2 receptor agonist-4 improves motor dysfunction and exerts neuroprotective effects in mouse models of Parkinson's disease. Dopamine D2 receptor agonist-4 can be used in studies related to Parkinson's disease.

5-OH-DPAT (5-Hydroxy-DPAT) is a potent and selective dopamine D2-receptor agonist lacking effects at 5-HT receptors. 5-OH-DPAT produces a moderate facilitation of the male rat sexual behavior.

Rotigotine (Hydrochloride) (Standard) is the analytical standard of Rotigotine (Hydrochloride). This product is intended for research and analytical applications. Rotigotine Hydrochloride (N-0923 Hydrochloride) is a full agonist of dopamine receptor, a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor, with K_i of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor.